This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy
and safety of bb2121 in subjects with relapsed and refractory MM (Cohort 1), in subjects with
MM having progressed within one 18 months of initial treatment including autologous stem cell
transplantation (ASCT) (Cohort 2a), and without ASCT (Cohort 2b) or, in subjects with
inadequate response post ASCT during initial treatment (Cohort 2c). Approximately 235
subjects will be enrolled into one of three cohorts. Cohort 1 will enroll approximately 97
RRMM subjects with ≥ 3 prior anti-myeloma treatment regimens. Cohort 2a will enroll
approximately 39 MM subjects, with 1 prior anti-myeloma therapy including ASCT and with early
relapse. Cohort 2b will enroll approximately 39 MM subjects with 1 prior anti-myeloma therapy
not including ASCT and with early relapse. Cohort 2c will enroll approximately 30 MM subjects
with inadequate response to ASCT during their initial anti-myeloma therapy. The cohorts will
start in parallel and independently. Cohort 3 will enroll approximately 30 newly diagnosed
multiple myeloma (NDMM) participants with suboptimal response to ASCT.
Anti-myeloma bridging treatment is allowed for disease control while bb2121 is being
manufactured for cohorts 1, 2a and 2b only.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.